Skip to Content

Join the 'Hemophilia A with Inhibitors' group to help and get support from people like you.

Hemophilia A with Inhibitors News

2 New Findings Offer Hope for Those With Severe Hemophilia

Posted 26 May 2016 by Drugs.com

WEDNESDAY, May 25, 2016 – Two new studies could pave the way to major changes in how doctors treat severe cases of hemophilia – a rare genetic disorder that can cause uncontrolled bleeding. Both studies tackle a key challenge: Up to one-third of children with severe hemophilia develop antibodies against the standard therapy. But one study highlights the value of an old therapy, while the other shows promising early results with an experimental drug. Experts said both should stir discussion among doctors, patients and parents who deal with hemophilia. But they were especially hopeful about the new drug, known as emicizumab. In the United States, about 20,000 people – mostly boys and men – are living with hemophilia, according to the U.S. Centers for Disease Control and Prevention. The disorder is caused by a defect in one of the genes that controls proteins needed for normal blood ... Read more

Related support groups: Blood Disorders, Bleeding Disorder, Anemia, Blood Transfusion, Hemophilia A, Hemophilia, Coagulation Defects and Disorders, Hemophilia B, Hemophilia A with Inhibitors, Blood Cell Transplantation

Review Finds Mixed Success With Hemophilia Treatment

Posted 16 Mar 2016 by Drugs.com

WEDNESDAY, March 16, 2016 – Though the past 50 years have brought major treatment advances, men with severe hemophilia are still at high risk for bleeding and physical disability, experts say. Hemophilia is a genetic disease that prevents blood from clotting normally, leading to an increased risk of serious bleeding. More common in men than in women, it affects about one out of every 5,000 men, according to the U.S. Centers for Disease Control and Prevention. Researchers analyzed data from nearly 7,500 male hemophilia patients in the United States between 1998 and 2011. Their findings were published online March 16 in the journal Blood. "Our analysis provides a snapshot of how improvements in care have translated into outcomes across different generations of men with hemophilia," study author Dr. Paul Monahan said in a journal news release. Monahan is a former professor of hematology ... Read more

Related support groups: Blood Disorders, Bleeding Disorder, Hemophilia A, Hemophilia, Coagulation Defects and Disorders, Hemophilia B, Hemophilia A with Inhibitors

Kids' Hemophilia Drugs a Big Part of State Medicaid Spending

Posted 31 Jul 2015 by Drugs.com

FRIDAY, July 31, 2015 – Treatment costs for one childhood illness, hemophilia, may use up a big chunk of a state's Medicaid budget, a new study out of California shows. The researchers found that treatments for hemophilia – a rare, inherited disorder in which blood does not clot normally – accounted for the largest share of spending on outpatient drugs among publicly insured children in California with serious chronic illnesses. The study "underscores the potential effect of new, expensive but [effective] pharmaceuticals on public insurance programs for children with chronic illness," wrote a group led by Sonja Swenson of Stanford University. Her team published the findings July 28 in the Journal of the American Medical Association. The researchers tracked 2010-2012 data from more than 34,300 publicly insured children and young adults under the age of 21 in California with serious ... Read more

Related support groups: Hemophilia A, Hemophilia B, Hemophilia, Antihemophilic Factor, Advate, ReFacto, Humate-P, Wilstart, Monarc-M, NovoEight, Fanhdi, Koate-DVI, Monoclate-P, Obizur, Haemate P, Kogenate, Alphanate, Recombinate, Helixate FS, Kogenate FS

Ask a Question

Further Information

Related Condition Support Groups

Hemophilia A

Related Drug Support Groups

Bebulin VH, Bebulin, Profilnine SD, Konyne 80, Proplex T, factor ix complex